Phagenesis Ltd
Cari Manypenny has a diverse work experience in the healthcare industry. They began their career in 2009 as a Speech-Language Pathologist at Marianjoy Rehabilitation Hospital. In 2015, they transitioned to the role of Clinical Development Coordinator at the same hospital, where they stayed until 2021. During their time at Marianjoy Rehabilitation Hospital, Cari also worked as a Clinical Specialist at Phagenesis Ltd from 2017 to 2021. In February 2021, they became the Manager of Clinical Development at Phagenesis Ltd.
Cari Manypenny's education history begins in 2003 when they enrolled at Illinois State University to pursue a Bachelor's degree in Speech Pathology and Audiology. Cari completed their undergraduate studies in 2007. After obtaining their Bachelor's degree, Cari continued their education at the same institution, Illinois State University, from 2007 to 2009 to earn a Master's degree in Communication Sciences and Disorders.
This person is not in any offices
Phagenesis Ltd
1 followers
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.